<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629729</url>
  </required_header>
  <id_info>
    <org_study_id>FT819-101</org_study_id>
    <nct_id>NCT04629729</nct_id>
  </id_info>
  <brief_title>FT819 in Subjects With B-cell Malignancies</brief_title>
  <official_title>A Phase I Study of FT819 in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in&#xD;
      subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor&#xD;
      B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an&#xD;
      expansion stage where participants will be enrolled into indication-specific cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2039</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities within each dose level cohort</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, and severity of adverse events (AEs) of FT819 as monotherapy and in combination with IL-2 in r/r B-cell lymphoma, r/r chronic lymphocytic leukemia, and r/r precursor B-cell acute lymphoblastic leukemia</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed objective-response rate (ORR)</measure>
    <time_frame>From baseline assessment up to approximately 2 years after last dose of FT819</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For BCL and CLL Only: Investigator-assessed duration of objective response (DOR)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For BCL and CLL Only: Investigator-assessed duration of complete response (DoCR)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For BCL and CLL Only: Progression-free survival (PFS)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the pharmacokinetics of FT819 cells in peripheral blood.</measure>
    <time_frame>Study Days 1, 2, 3, 4, 5, 6, 8, 11, 15, 18, 22, 25, and 29</time_frame>
    <description>The PK of FT819 in peripheral blood will be reported as the relative percentage of product (FT819) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For B-ALL Only: Investigator-assessed relapse-free survival (RFS)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">297</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Precursor B-Cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Single-Dose Monotherapy, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose monotherapy in adult subjects with r/r CLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Step Fractionated Monotherapy, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose monotherapy in adult subjects with r/r B-ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT819</intervention_name>
    <description>Experimental Interventional Therapy</description>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, CLL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, CLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, CLL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, CLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, CLL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-ALL</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Step Fractionated Monotherapy, CLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Biologic response modifier</description>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-ALL</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma</arm_group_label>
    <arm_group_label>FT819 Single-Dose in Combination with IL-2, CLL</arm_group_label>
    <other_name>Interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of B-cell lymphoma, CLL or B-ALL as described below:&#xD;
&#xD;
        B-Cell Lymphoma:&#xD;
&#xD;
          -  Histologically documented lymphomas expected to express CD19&#xD;
&#xD;
          -  Relapsed/refractory disease following at least 2 prior lines of multi-agent&#xD;
             immunochemotherapy&#xD;
&#xD;
        Chronic Lymphocytic Leukemia (CLL):&#xD;
&#xD;
          -  Diagnosis of CLL per iwCLL guidelines&#xD;
&#xD;
          -  Relapsed/refractory disease following at least two prior systemic treatment regimens&#xD;
&#xD;
        Precursor B-cell Acute Lymphocytic Leukemia (B-ALL):&#xD;
&#xD;
          -  Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics&#xD;
&#xD;
          -  Relapsed/refractory disease after at least 2 cycles of standard multiagent induction&#xD;
             chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease,&#xD;
             failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen&#xD;
&#xD;
        ALL SUBJECTS:&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Stated willingness to comply with study procedures and duration&#xD;
&#xD;
          -  Contraceptive use for women and men as defined in the protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        ALL SUBJECTS:&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2&#xD;
&#xD;
          -  Body weight &lt;50 kg&#xD;
&#xD;
          -  Evidence of insufficient organ function&#xD;
&#xD;
          -  Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is&#xD;
             shorter; or any investigational therapy within 28 days prior to Day 1&#xD;
&#xD;
          -  Currently receiving or likely to require systemic immunosuppressive therapy&#xD;
&#xD;
          -  Ongoing requirement for systemic GvHD therapy following prior allogeneic hematopoietic&#xD;
             stem cell transplant (HSCT) or allogeneic CAR-T&#xD;
&#xD;
          -  Receipt of an allograft organ transplant&#xD;
&#xD;
          -  Known active central nervous system (CNS) involvement by malignancy&#xD;
&#xD;
          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or&#xD;
             neurodegenerative disease&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Positive serologic test results for HIV infection&#xD;
&#xD;
          -  Positive serologic or polymerase chain reaction (PCR) test results for Hepatitis B&#xD;
             (HBV) infection&#xD;
&#xD;
          -  Positive serologic and PCR test results for Hepatitis C (HCV) infection&#xD;
&#xD;
          -  Live vaccine &lt;6 weeks prior to start of lympho-conditioning&#xD;
&#xD;
          -  Known allergy to albumin (human) or DMSO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Elstrom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Reynolds</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamuna Thimmarayappa</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1182/blood-2019-130584</url>
    <description>FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial</description>
  </link>
  <link>
    <url>https://cancerres.aacrjournals.org/content/80/16_Supplement/3245</url>
    <description>AACR 2020 Poster # 3245</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>BCL</keyword>
  <keyword>CLL</keyword>
  <keyword>B-ALL</keyword>
  <keyword>CAR-T</keyword>
  <keyword>cellular therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

